Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006

Haworth, S G; Hislop, A A
February 2009
Heart;Feb2009, Vol. 95 Issue 4, p312
Academic Journal
Objective: A retrospective study of the UK Pulmonary Hypertension Service for Children for the first 5-year period of its existence. Design and patients: Records of 216 children with idiopathic pulmonary arterial hypertension (IPAH) and associated pulmonary arterial hypertension (APAH) were reviewed. Kaplan-Meier survival curves were constructed for different diagnostic groups and for different therapies. Results: At cardiac catheterisation only 7.4% of those with IPAH and 6% of those with APAH responded positively to vasodilator testing and so were treated with nifedipine. Others needing treatment were given continuous intravenous epoprostenol, bosentan or sildenafil singly or in combination. For IPAH survival rates were 85.6%, 79.9% and 71.9% at 1, 3 and 5 years, respectively, compared with a survival time of less than a year in historical untreated controls. A combination of intravenous epoprostenol with either bosentan or sildenafil, or both, appeared to achieve the best outcome. Six children underwent lung transplantation. In APAH survival rates were 92.3%, 83.8% and 56.9% at 1, 3 and 5 years, respectively, postoperative congenital heart disease with severe pulmonary hypertension having the worst outcome. Conclusion: New pulmonary hypertension-specific medicines have improved survival in children as in adults. Outcome in this series compares favourably with international outcome data.


Related Articles

  • Guest Editor's Memo. Ivy, Dunbar; Krishnan, Usha // Advances in Pulmonary Hypertension;2016, Vol. 15 Issue 2, p58 

    The article discusses diagnosis and treatment of children with pulmonary hypertension.

  • PULMONARY ARTERY HYPERTENSION: NEW DRUG TREATMENT IN CHILDREN. Ford, Katrina // Archives of Disease in Childhood -- Education & Practice Edition;Jun2005, Vol. 90 Issue 1, p15 

    Focuses on the key trials of drugs for children marketed for the treatment of pulmonary artery hypertension (PAH) in Great Britain. Diagnostic classification and definitions of idiopathic pulmonary artery hypertension and familial pulmonary artery hypertension; Components of the drugs...

  • PULMONARY HYPERTENSION IN THE YOUNG. Haworth, Sheila G. // Heart;Dec2002, Vol. 88 Issue 6, p658 

    Focuses on forms of pulmonary arterial hypertension in the children. Failure of pulmonary circulation to adapt to extrauterine life; Diagnosis of pulmonary hypertension in children; Role of genetic predisposition in intracardiac abnormality.

  • Inaugural Scientific Meeting of the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) Sydney, Australia 25 November, 2011.  // Pulmonary Circulation;2011, Vol. 1 Issue 4, pS33 

    The article presents abstracts on medical topics which include Abnormal pulmonary artery stiffness in pulmonary arterial hypertension, Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis, and chronic thromboembolic pulmonary hypertension.

  • PH Professional Network: Dental Care in Children With Pulmonary Hypertension. Brady, Daniela; Devereux, Jane // Advances in Pulmonary Hypertension;2016, Vol. 15 Issue 2, p70 

    The article discusses dental care in children with pulmonary hypertension.

  • FDA clarifies sildenafil warning in children.  // Reactions Weekly;Apr2014, Vol. 1496 Issue 1, p2 

    The article reports that the U.S. FDA has clarified that revatio (sildenafil) is not recommended for the treatment of pulmonary arterial hypertension (PAH) in children.

  • An Update on Therapies for Pediatric Pulmonary Arterial Hypertension 2011. Yung, Delphine // Advances in Pulmonary Hypertension;Summer2011, Vol. 10 Issue 3, p109 

    The article provides updates in the treatment of pulmonary arterial hypertension (PAH) in children, highlighting the growing numbers of approved therapies for pulmonary hypertension. It examines the literature associated to pediatric use of those therapies and discusses the evidence-based...

  • Evaluation of pulmonary vascular resistance and vasoreactivity testing with oxygen in children with congenital heart disease and pulmonary arterial hypertension. Çevik, Ayhan; Kula, Serdar; Olguntürk, Rana; Tunaoğlu, Sedef; Oğuz, Deniz; Saylan, Berna; Şanlı, Cihat // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Mar2014, Vol. 14 Issue 2, p196 

    The article offers information related to pulmonary vascular resistance and vasoreactivity testing in children with congenital heart disease and pulmonary arterial hypertension. Topics discussed include pulmonary vascular resistance index (PVRI), positive pulmonary vasoreactivity test (PVT) and...

  • Imatinib for the Treatment of Pulmonary Arterial Hypertension. Ghofrani, Hossein A.; Seeger, Werner; Grimminger, Friedrich // New England Journal of Medicine;9/29/2005, Vol. 353 Issue 13, p1412 

    A letter to the editor is presented about the efficacy of imatinib in the treatment of pulmonary arterial hypertension.


Read the Article


Sign out of this library

Other Topics